Antallet af patienter, som havde fået rituximab som en del af deres induktionsbehandling, var imidlertid for lavt til at afgøre, om det ville have været en fordel at anvende Zevalin som konsoliderende behandling hos disse patienter.
However, there were too few patients who had received rituximab as part of their induction treatment to determine whether there would be a benefit of using Zevalin as consolidation treatment in these patients.